- Demand for biosimilars for a range of chronic diseases and cancers gathers momentum from their low cost of production and efficacy comparable to the reference biologics
ALBANY, New York, Feb. 20, 2020 /PRNewswire/ -- Large patent expiry of biologics in next few years has imparted an increasingly high momentum to the development of biosimilars. The prevalence of biosimilars has benefitted from their demand in oncology, particularly from the role of monoclonal antibodies in numerous cancer treatments, according to a study by TMR. The global Biosimilars Market is expected to reach a value of ~US$ 21.1 bn by the end of 2027 and is projected to garner a CAGR of ~23% during 2019–2027. The valuation of the market was pegged at ~US$ 8 bn in 2018.
Drug makers and healthcare companies will benefit from the increasing rate approval of biosimilars in developed nations.
"Manufacturers are harnessing a growing body of clinical studies to prove analytical similarity with originators and unveil biosimilars that are worthy of approvals. They should invest in developing economies of Asia Pacific to tap new revenue streams," opine analysts at TMR.
Key Findings of Biosimilars Market Study
- Among the various product types, recombinant glycosylated proteins is a prominent revenue generator for the biosimilars market; the segment is expected to touch valuation of ~US$ 23.5 bn by 2027.
- Of all the indications, oncology led the global market by holding the major share in 2018. The segment is expected to retain its dominance throughout the remaining period of the assessment period.
- Further, recombinant non-glycosylated proteins is anticipated to account for a major share during the forecast period. The major growth impetus will come from the attractive growth of opportunities in the insulin sub-segment; it also held the major share in the segment in 2018
- Of all the major regions, Europe held the major share in the global biosimilars market in 2018.
Explore 232 pages of top-notch research, incisive insights, and detailed country-level projections. Gain business intelligence on Biosimilars Market (Product: Recombinant Glycosylated Proteins [Monoclonal Antibodies, Erythropoietin, and Others], Recombinant Non-glycosylated Proteins [Insulin, Granulocyte Colony Stimulating Factor, Recombinant Human Growth Factor, and Interferons], and Recombinant Peptides; and Indication: Chronic Diseases, Oncology, Autoimmune Diseases, Infectious Diseases, Blood Disorders, Growth Hormone Deficiency, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 – 2027 at https://www.transparencymarketresearch.com/report-toc/118
Biosimilars Market: Key Driving Factors
A study by Transparency Market Research highlights numerous healthcare trends driving need for biosimilars development world over. A few trends are worth noticing:
- Increasing prevalence of diabetes in recent years has spurred interest of biotechnology companies in biosimilars insulin. According to the International Diabetes Federation (IDF), the diabetes prevalence globally in 2019 was estimated to be 9.3%, and is expected to rise to 10.2% by 2030, and further to 10.9% by 2045.
- Growing number of monoclonal antibodies approved by the U.S. FDA for the treatment of cancer has bolstered prospects in the biosimilars market. According to the Antibody Society in the U.S., more than 16 antibody biosimilar therapeutics were approved during the period 2015–2019. Such approvals are helpful in potentially reducing the cost of treatment of cancer.
- Increasing global burden of chronic diseases expands the avenue for the acceptance of biosimilars among patient populations. Chronic diseases are the key cause of death and disability. According to the WHO, by 2020 their contribution is estimated to reach 73% of all deaths.
Download a PDF Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=118
Key Impediments for Biosimilars Market Players
Though the biosimilars market is on an attractive growth trajectory, a few factors hinder their preference over the reference biologics and hamper their uptake in patient population.
- One key bottleneck is prolonged clinical development pathways, particularly for orphan biosimilars. This is due to the lack of clinical data to support the efficacy of rare disease drugs.
- The affordability of biosimilars is still get established worldwide.
However, large unmet demand in Asia Pacific will impart a significant momentum to future expansion of the market.
Biosimilars Market: Region-wise Analysis
Geographically, Europe dominated the market in 2018. The penetration of biosimilars could be attributed to the high significantly lower price compared to the reference biologics and efforts by the healthcare systems to adopt affordable treatments for the management of diseases.
On the other hand, Asia Pacific is a market with sizable opportunities for the development of biosimilars. The regional market is expected to grow at promising pace during 2019 – 2027. Marked prevalence of chronic conditions and autoimmune diseases has driven the demand for biologics, hence catalyzing the need for biosimilars.
Analyze biosimilars market growth in 30+ countries including US, Canada, Germany, United Kingdom, India, China, and South Korea. Request a sample of the study.
Companies intending to up their stakes in the biosimilars market have increased their efforts in reducing the cost of treatment for cancer patients by offering those biosimilars. Also, most players are geared toward conducting more clinical studies to establish the effectiveness and safety of their biosimilars formulations with the reference biologics. To this end, they are also mulling increased numbers of collaborations. A few players in the biosimilars market are also bolstering their product portfolio expansion in order to strengthen their positions in coming few years.
Some of the well-entrenched players include names such as Apotex Inc., Amgen, Inc., Celltrion Inc., Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Biocon, and Pfizer, Inc.
The biosimilars market is segmented on the basis of:
- Recombinant Glycosylated Proteins
- Monoclonal Antibodies
- Recombinant Non-glycosylated Proteins
- Granulocyte Colony Stimulating Factor
- Recombinant Human Growth Factor
- Recombinant Peptides
Biosimilars Market, by Indication
- Chronic Diseases
- Autoimmune Diseases
- Infectious Diseases
- Blood Disorders
- Growth Hormone Deficiency
Biosimilars Market, by Region
- North America
- Rest of Europe
- Asia Pacific
- Australia & New Zealand
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Explore Transparency Market Research's award-winning coverage of the global Healthcare industry:
Gene Editing Technology Market - There are several factors that are helping to drive the development of the global gene editing technology market. One of the most notable trends in the global market has been the growing prevalence of chronic disorders such as cardiovascular diseases, cancer, genetic diseases, and neural disorders among others.
Chronic Lymphocytic Leukemia Market - Increasing incidence of cancer across the globe, innovative drug therapy, fast regulatory approval process, and aggressive pipeline for chronic lymphocytic leukemia treatment drugs are the factors driving the growth of the global chronic lymphocytic leukemia market. However, lack of awareness regarding symptoms at an early stage, low accessibility of treatment options in under-developed countries, increasing use of generic products across countries hampering the demand for branded drugs, and adverse events occurring during the treatment, such as side effects of chemotherapy, are restraining the growth of the global market.
Monoclonal Antibodies Market - The report provides a detailed analysis of the opportunities and trends in the global monoclonal antibodies market. It segments the global market based on different parameters in order to study them in depth with expert inputs from industry veterans. The report provides a detailed assessment of the prevailing vendor landscape. It also profiles the leading players operating in the market and leveraging industry-leading analytical tools, gauges the threats and opportunities that these companies may face over the course of the forecast period between 2016 and 2024.
DNA and RNA Sample Preparation Market - The report finds that numerous factors are benefitting the uptake of DNA and RNA sample preparation. Those include increased allocation on medical research to find cures for various health conditions. Continued improvement in underpinning technologies is also having a positive impact on the market.
Gain access to Market Ngage, an AI-powered, real-time business intelligence that goes beyond the archaic research solutions to solve the complex strategy challenges that organizations face today. With over 15,000+ global and country-wise reports across 50,000+ application areas, Market Ngage is your tool for research on-the-go. From tracking new investment avenues to keeping a track of your competitor's moves, Market Ngage provides you with all the essential information to up your strategic game. Power your business with Market Ngage's actionable insights and remove the guesswork in making colossal decisions.
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision."
Transparency Market Research
90 State Street,
Albany NY - 12207
USA - Canada Toll Free: 866-552-3453
SOURCE Transparency Market Research